Compare AU

Compare CURE vs. FLOT

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the VanEck Australian Floating Rate ETF (FLOT). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

CURE

FLOT

Popularity

Low

Low

Pearlers invested

79

5

Median incremental investment

$620.50

$2,126.36

Median investment frequency

Monthly

Fortnightly

Median total investment

$1,443.96

$14,677.88

Average age group

> 35

> 35


Key Summary

CURE

FLOT

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

FLOT.AX was created on 2017-07-05 by VanEck. The fund's investment portfolio concentrates primarily on investment grade fixed income. The ETF currently has 750.5m in AUM and 194 holdings. The VanEck Australian Floating Rate ETF invests in a diversified portfolio of Australian dollar denominated floating rate bonds with the aim of providing investment returns (before management costs) that closely track the returns of the Bloomberg AusBond Credit FRN 0+ Yr Index.

Top 3 holdings

Neurocrine Biosciences Inc (2.75 %)

Alnylam Pharmaceuticals Inc (2.52 %)

Insmed Inc (2.46 %)

Westpac Banking Corp. (2.53 %)

National Australia Bank Ltd. (2.52 %)

Westpac Banking Corp. (2.20 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.22 %


Key Summary

CURE

FLOT

Issuer

Global X

VanEck

Tracking index

S&P Biotechnology Select Industry

Bloomberg AusBond Credit FRN 0+ Yr Index - AUD

Asset class

ETF

ETF

Management fee

0.45 %

0.22 %

Price

$51.57

$24.92

Size

$34.226 million

$759.762 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

4.24 %

2.65 %

Market

ASX

ASX

First listed date

12/11/2018

07/07/2017

Purchase fee

$6.50

$6.50


Community Stats

CURE

FLOT

Popularity

Low

Low

Pearlers invested

79

5

Median incremental investment

$620.50

$2,126.36

Median investment frequency

Monthly

Fortnightly

Median total investment

$1,443.96

$14,677.88

Average age group

> 35

> 35


Pros and Cons

CURE

FLOT

Pros

  • Higher exposure to US market

  • Higher distribution yield

  • Lower management fee

  • Higher price growth

Cons

  • Higher management fee

  • Lower price growth

  • Lower exposure to US market

  • Lower distribution yield

CURE

FLOT

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home